Data compiled by Redley Lamar · ChainSifter Intelligence
11Suppliers
5Customers
3Debt Items
11Related Chains
Source-Backed Evidence Depth
Xenetic Biosciences, Inc. (XBIO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
19Total relationships
3Distinct source URLs
15High confidence
0.814Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Xenetic Biosciences, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CATALENT-PHARMA-SOLUTIONS-LLC
CATALENT-PHARMA-SOLUTIONS-LLC
92%
The Company entered into a Statement of Work with Catalent to outline the general scope of work, timeline, and pricing pursuant to which Catalent will provide certain services to the Company to perfo…
SCRIPPS-RESEARCH
SCRIPPS-RESEARCH
90%
· Scripps Research, one of the world’s largest, private non-profit research organizations
PERINESS-LTD
PERINESS-LTD
85%
The Company has entered into various research, development, license and supply agreements with PeriNess Ltd.
SYNBIO
SYNBIO
85%
The Company granted an exclusive license to SynBio to develop, market and commercialize certain drug candidates utilizing molecules based on SynBio’s technology and the Company’s proprietary technologies
UVA
UVA
85%
The Company paid UVA approximately $ 0.6 million under the UVA Agreement through March 31, 2026
PERINESS
PERINESS
80%
· PeriNess, a privately held Israeli company focused on the use of DNase I in male infertility
PHARMSYNTHEZ
PHARMSYNTHEZ
80%
The Company granted an exclusive license to Pharmsynthez to develop, commercialize and market six product candidates based on the Company’s PolyXen and ImuXen technology in certain territories
PJSC-PHARMSYNTHEZ
PJSC-PHARMSYNTHEZ
80%
The Company has also entered into various research, development, license and supply agreements with PJSC Pharmsynthez
SERUM-INSTITUTE-OF-INDIA
SERUM-INSTITUTE-OF-INDIA
80%
The Company has also entered into various research, development, license and supply agreements with Serum Institute of India
SYNBIO-LLC
SYNBIO-LLC
80%
The Company has also entered into various research, development, license and supply agreements with SynBio LLC
Reciprocal relationship from OPK graph: Reciprocal relationship from XBIO graph: Reciprocal relationship from OPK graph: ence over the particular investee and whether the particular equity security h…
Xenetic Biosciences, Inc. Customers
Ticker
Name
Confidence
Evidence
TAKEDA-PHARMACEUTICALS-CO-LTD
TAKEDA-PHARMACEUTICALS-CO-LTD
92%
Royalty payments of approximately $ 0.8 million and $ 0.6 million were recorded as revenue during the three months ended March 31, 2026 and 2025, respectively, and are based on single digit royalties…
PERINESS-LTD
PERINESS-LTD
90%
During the fourth quarter of 2024, the Company entered into a clinical trial services agreement with PeriNess Ltd. to advance the Company’s development program for its systemic DNase I technology in …
CLS-THERAPEUTICS-LTD
CLS-THERAPEUTICS-LTD
62%
nnual Report on Form 10-K. Some of the principal risks relating to our business include: · The outcome and timing of the strategic review process being conducted by the Company’s Board and a special …
INDIA-LIMITED
INDIA-LIMITED
62%
ez filed a registration dossier to obtain approval in Russia and informed the Company that it has received a response letter indicating certain deficiencies in the dossier. Pharmsynthez further infor…
SYMBIOTEC-GMBH
SYMBIOTEC-GMBH
62%
nnual Report on Form 10-K. Some of the principal risks relating to our business include: · The outcome and timing of the strategic review process being conducted by the Company’s Board and a special …
Xenetic Biosciences, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
XBIO-DEBT-13639
Warrants outstanding: 29.09
90%
xbrl warrant detail from xbrl 2026-03-31.
XBIO-DEBT-13640
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2016-12-31.
XBIO-DEBT
Debt stack $585,626
90%
Market cache reports total debt of $585,626.
Xenetic Biosciences, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Xenetic Biosciences, Inc..
Xenetic Biosciences, Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for Xenetic Biosciences, Inc..
Xenetic Biosciences, Inc. Extended Supply Chain Network
